I’m surprised the price is still so low after such a bullish announcement. Guessing the institutional traders/investors must still be getting adjusted to life back at the office after a decent break. These are the hard numbers that prove iTrack Advance is indeed a best in class treatment that will grow rapidly in sales and become a gold standard of treatment for Glaucoma. If they could get 65% growth even with everything that was going on towards the end of last year, well that’s a pretty amazing accomplishment. Very surprised that the market is still clearly asleep with this one.
Ann: USA Sales Update, page-31
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $51.48M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 23.0¢ | 22.0¢ | $86.46K | 381.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 37084 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 41303 | 1 |
View Market Depth
| Last trade - 12.05pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
22.5¢ |
Change
0.000 ( 2.27 %) |
||||
| Open | High | Low | Volume | ||
| 22.5¢ | 23.0¢ | 22.5¢ | 194734 | ||
| Last updated 12.06pm 17/06/2024 ? | |||||
| EYE (ASX) Chart |
